Pharmasyntez

Pharmasyntez is a leading Russian biopharmaceutical company focused on enhancing patient access to high-quality, modern medications. Founded in 1997, its core mission is developing and producing critical drugs for tuberculosis, HIV/AIDS, and oncological diseases, addressing significant public health challenges. Pharmasyntez leverages its pharmaceutical development expertise to create stable, effective treatments, aiming to save lives through innovative medicine.

The company operates seven manufacturing facilities across Russia, supporting a workforce of over 6,000 highly qualified pharmaceutical specialists. Pharmasyntez actively fosters collaborations with domestic and international pharmaceutical entities, underscoring its commitment to global health. To understand the individuals driving these efforts, explore Meet Pharmasyntez's team. This extensive infrastructure enables rigorous production standards and expanded therapeutic reach.

With a reported revenue of $53.9M and an employee range of 1,000-5,000 employees, Pharmasyntez demonstrates significant scale within the pharmaceutical sector. Its commitment to quality is a cornerstone of its operations, ensuring all medications meet stringent standards. The company's product portfolio, encompassing essential drugs and pharmaceuticals, is vital for public health. Pharmasyntez's dedication to innovation and its strategic position in the Russian healthcare landscape make it a key player in the biopharmaceutical industry, contributing to advancements in disease treatment and patient care.